Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1
文献类型：期刊论文
| 作者 | Xia Peng1; Pengcong Hou1; Yi Chen1 ; Yang Dai1; Yinchun Ji1; Yanyan Shen1; Yi Su1; Bo Liu1; Yueliang Wang1; Deqiao Sun1
|
| 刊名 | Journal of Experimental & Clinical Cancer Research
 |
| 出版日期 | 2019 |
| 卷号 | 38期号:1 |
| ISSN号 | 1756-9966 |
| 英文摘要 | The interaction between tumor cells and their immunosuppressive microenvironment promotes tumor progression and drug resistance. Thus, simultaneously targeting tumor cells and stromal cells is expected to have synergistic antitumor effects. Herein, we present for the first time a preclinical antitumor investigation of 3D185, a novel dual inhibitor targeting FGFRs, which are oncogenic drivers, and CSF-1R, which is the major survival factor for protumor macrophages. |
| 语种 | 英语 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/298613]  |
| 专题 | 中国科学院上海药物研究所 |
| 作者单位 | 1.Shanghai Institute of Materia Medica, Chinese Academy of Sciences 2.中国科学院大学 3.Shanghai HaiHe Pharmaceutical Co., Ltd |
| 推荐引用方式 GB/T 7714 | Xia Peng,Pengcong Hou,Yi Chen,et al. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1[J]. Journal of Experimental & Clinical Cancer Research,2019,38(1). |
| APA | Xia Peng.,Pengcong Hou.,Yi Chen.,Yang Dai.,Yinchun Ji.,...&Jing Ai.(2019).Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1.Journal of Experimental & Clinical Cancer Research,38(1). |
| MLA | Xia Peng,et al."Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1".Journal of Experimental & Clinical Cancer Research 38.1(2019). |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。